SCHEMBL20119647

SCHEMBL20119647

Cc1c[nH]c2nc(Cl)nc(NCc3nccs3)c12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.38
ESR1 P03372 4/20 0.37
KHK P50053 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PIM1 P11309 3/20 0.35
DYRK1A Q13627 3/20 0.35
DYRK2 Q92630 2/20 0.35
DYRK1B Q9Y463 2/20 0.35
TRPM5 Q9NZQ8 1/20 0.34
CHRM4 P08173 1/20 0.34
SYK P43405 1/20 0.33
TLR7 Q9NYK1 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
IGF1R P08069 1/20 0.31
KDM1A O60341 1/20 0.31
MAOB P27338 1/20 0.31
ROCK2 O75116 1/20 0.31
LIMK1 P53667 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119881 0.88 HRH4 (0.37) HRH4ESR1KHKSMN1; SMN2PIM1
SCHEMBL20119563 0.86 HRH4 (0.36) HRH4ESR1SMN1; SMN2PIM1DYRK1A
SCHEMBL20119976 0.82 CHUK (0.45) HRH4SMN1; SMN2ROCK2
SCHEMBL20119582 0.76 SMN1; SMN2 (0.42) HRH4KHKSMN1; SMN2DYRK1ADYRK1B
SCHEMBL20119884 0.76 ESR1 (0.44) ESR1PIM1DYRK1ADYRK2DYRK1B
SCHEMBL20119978 0.76 HRH4 (0.44) HRH4KHKSMN1; SMN2DYRK1ADYRK1B
SCHEMBL20119691 0.75 HRH4 (0.43) HRH4KHKSMN1; SMN2DYRK1ADYRK1B
SCHEMBL20119730 0.75 PIM1 (0.38) ESR1PIM1DYRK1ADYRK2DYRK1B
SCHEMBL20119716 0.73 HRH4 (0.39) HRH4ESR1KHKTRPM5CHRM4
SCHEMBL17933819 0.72 PLK4 (0.41) HRH4SMN1; SMN2DYRK1ADYRK1BTRPM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885ESR1 4474/4885KHK 2342/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885ESR1 4474/4885KHK 2342/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885ESR1 4474/4885KHK 2342/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885ESR1 4474/4885KHK 2342/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885ESR1 4474/4885KHK 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.